INTELLIA THERAPEUTICS INC
NASDAQ: NTLA (Intellia Therapeutics, Inc.)
Kemas kini terakhir: 4 jam lalu15.67
0.47 (3.09%)
| Penutupan Terdahulu | 15.20 |
| Buka | 15.53 |
| Jumlah Dagangan | 8,849,172 |
| Purata Dagangan (3B) | 6,377,575 |
| Modal Pasaran | 2,189,447,936 |
| Harga / Jualan (P/S) | 22.07 |
| Harga / Buku (P/B) | 2.72 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2026 |
| Margin Operasi (TTM) | -726.57% |
| EPS Cair (TTM) | -5.23 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -42.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 15.29% |
| Nisbah Semasa (MRQ) | 4.90 |
| Aliran Tunai Operasi (OCF TTM) | -377.15 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -150.18 M |
| Pulangan Atas Aset (ROA TTM) | -30.12% |
| Pulangan Atas Ekuiti (ROE TTM) | -57.92% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Intellia Therapeutics, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | 1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.60 |
|
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.98% |
| % Dimiliki oleh Institusi | 97.04% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 31 Mar 2026 | 3,702,995 |
| Two Sigma Advisers, Lp | 31 Dec 2025 | 2,346,317 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BHANJI MUNA | 12.89 | - | 9,200 | 118,588 |
| CHASE WILLIAM J | 12.89 | - | 9,200 | 118,588 |
| COHEN FRED E | 12.89 | - | 9,200 | 118,588 |
| GOFF BRIAN | 12.89 | - | 9,200 | 118,588 |
| GOODMAN JESSE | 12.89 | - | 9,200 | 118,588 |
| KERESTY GEORGIA | 12.89 | - | 9,200 | 118,588 |
| VERWIEL FRANK | 12.89 | - | 9,200 | 118,588 |
| Jumlah Keseluruhan Kuantiti Bersih | 64,400 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 830,116 | |||
| Purata Pembelian Keseluruhan ($) | 12.89 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| BHANJI MUNA | Pengarah | 09 Jun 2026 | Diperolehi (+) | 9,200 | 12.89 | 118,588 |
| CHASE WILLIAM J | Pengarah | 09 Jun 2026 | Diperolehi (+) | 9,200 | 12.89 | 118,588 |
| COHEN FRED E | Pengarah | 09 Jun 2026 | Diperolehi (+) | 9,200 | 12.89 | 118,588 |
| GOFF BRIAN | Pengarah | 09 Jun 2026 | Diperolehi (+) | 9,200 | 12.89 | 118,588 |
| GOODMAN JESSE | Pengarah | 09 Jun 2026 | Diperolehi (+) | 9,200 | 12.89 | 118,588 |
| KERESTY GEORGIA | Pengarah | 09 Jun 2026 | Diperolehi (+) | 9,200 | 12.89 | 118,588 |
| VERWIEL FRANK | Pengarah | 09 Jun 2026 | Diperolehi (+) | 9,200 | 12.89 | 118,588 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 27 Apr 2026 | CNBC | Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |